超声影像组学模型预测ER阳性乳腺癌晚期复发
本回顾性多中心研究纳入523例ER阳性乳腺癌患者,开发并验证基于超声的IHC4相关影像组学模型。模型在训练集、内部验证集及两个外部验证集的AUC分别为0.81、0.84、0.79、0.81。IHC4相关影像组学评分与无进展生存期相关,HR为4.246。
要点
- 超声IHC4相关影像组学评分可对ER阳性乳腺癌晚期远处复发风险进行分层。
- 该评分在多变量Cox分析中与无进展生存期相关,HR=4.246。
- 该模型可能作为非侵入性预后标志物,辅助延长内分泌治疗决策。
核心结论
- 基于超声的IHC4相关影像组学模型可作为预测ER阳性乳腺癌预后的非侵入性生物标志物。
- IHC4相关影像组学评分在训练集和各验证集中均能对晚期远处复发风险进行分层。
研究设计与样本
- 回顾性多中心研究,共纳入523例ER阳性乳腺癌患者,分为训练集、内部验证集和两个外部验证集。
- 选择与IHC4评分相关的影像组学特征构建基于支持向量机的超声IHC4相关影像组学模型。
- 以晚期远处复发为主要终点,无进展生存期为次要终点,采用Cox回归分析评估评分的预后价值。
关键影像表现/征象
- 共筛选出7个与IHC4相关的超声影像组学特征用于构建预测模型。
诊断标准与关键数值
- 模型在训练集、内部验证集和两个外部验证集的AUC分别为0.81、0.84、0.79、0.81。
临床应用与阅片要点
- 超声影像组学评分可用于ER阳性乳腺癌患者的晚期复发风险分层。
- 该评分可能为延长内分泌治疗的患者选择提供决策支持。
局限性
- 本研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to develop and validate an ultrasound-based IHC4-associated radiomic model for predicting late recurrence in ER-positive breast cancer and to evaluate its potential to support risk stratification and guide decisions on extended endocrine therapy.
METHODS: In this retrospective multicenter study, patients were divided into a training cohort, an internal validation cohort, and two external validation cohorts. Radiomic features associated with the immunohistochemical four-marker (IHC4) score were selected to construct a support vector machine (SVM)-based IHC4-associated radiomic model for generating an IHC4-associated radiomic score. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Late distant recurrence (DR) was defined as the primary endpoint, and progression-free survival (PFS) was defined as the secondary endpoint. The prognostic value of the score was further evaluated using Cox regression analysis.
RESULTS: A total of 523 patients were included in this study. Seven IHC4-associated radiomic features were selected to construct the IHC4-associated radiomic model. The model demonstrated consistent performance across cohorts, with AUCs of 0.81, 0.84, 0.79, and 0.81 in the training, internal validation, and two external validation cohorts, respectively. The IHC4-associated radiomic score stratified late DR risk across the training, internal validation, and external validation cohorts. In the secondary exploratory PFS analysis, the score remained associated with PFS in multivariable Cox analysis (HR = 4.246, 95% CI: 1.749-10.307, P = .001).
CONCLUSIONS: The IHC4-associated radiomic model may serve as a noninvasive biomarker for predicting prognosis in ER-positive breast cancer.
引用
- Quan, Wang, Yuan, et al. Ultrasound-Based IHC4-Associated Radiomic Model for Predicting Late Recurrence in ER-Positive Breast Cancer: A Multicenter Retrospective Study. J Ultrasound Med. 2026. PMID: 42581607. doi:10.1002/jum.70410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。